(Corrects spelling of company name in headline)
Nov 2(Reuters) - Oncology Venture A/S:
* ANNOUNCED ON THURSDAY ITS PLANS TO AIM FOR ITS FIRST MARKETING APPROVAL OF LIPLACIS BASED ON A SINGLE ARM PIVOTAL STUDY
* EXPECTS THAT A CLINICAL STUDY IN 100-200 PATIENTS WILL BE SUFFICIENT FOR A MARKETING APPROVAL OF LIPLACIS AS A NEW TREATMENT OF BREAST CANCER
* AIM IS A FIRST APPROVAL OF LIPLACIS BY A SINGLE ARM PIVOTAL STUDY
* SAID ONGOING PHASE 2 STUDY OF LIPLACIS MAY CONTINUE AND BRIDGE INTO SUCH A PIVOTAL TRIAL
Source text for Eikon:
Further company coverage: (Gdynia Newsroom)